SDC1 and plasma cell myeloma: For example, indatuximab ravtansine is a monoclonal antibody-related drug that particularly aims SDC1-expressing cells, pre-clinical research corroborated the activity of indatuximab ravtansine in combination with lenalidamide and examethasone for plasma cell myeloma, and a clinical research is continuous [37].